Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pliant Therapeutics, Inc.

1.59
+0.11007.43%
Post-market: 1.59-0.0007-0.04%19:04 EDT
Volume:843.45K
Turnover:1.30M
Market Cap:97.60M
PE:-0.46
High:1.60
Open:1.46
Low:1.43
Close:1.48
Loading ...

BRIEF-Pliant Therapeutics Provides Update On Beacon-IPF

Reuters
·
03 Mar

Pliant Therapeutucs Shares Halted After Bexotegrast Phase 2b Trial Discontinued

Dow Jones
·
03 Mar

Pliant Therapeutics Inc - Committed to Development of Other Clinical Assets Including Pln-101095 in Oncology

THOMSON REUTERS
·
03 Mar

Pliant Therapeutics Inc - Discontinues Beacon-Ipf Phase 2B Trial

THOMSON REUTERS
·
03 Mar

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

Simply Wall St.
·
18 Feb

TD Cowen Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

TIPRANKS
·
18 Feb

Positive Outlook on Pliant Therapeutics Despite Trial Uncertainty

TIPRANKS
·
17 Feb

All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

Zacks
·
15 Feb

Pliant Therapeutics Price Target Maintained With a $10.00/Share by Needham

Dow Jones
·
14 Feb

Sector Update: Health Care Stocks Mixed Thursday Afternoon

MT Newswires Live
·
14 Feb

Optimistic Buy Recommendation Amid Pliant Therapeutics’ Trial Review and Stock Surge

TIPRANKS
·
14 Feb

Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

MT Newswires Live
·
14 Feb

Pliant Therapeutics Shares Rise After Board Recommendations for Bexotegrast

Dow Jones
·
13 Feb

Pliant Therapeutics Announces Next Steps Following Dsmb Recommendation on Beacon-Ipf, a Phase 2B/3 Trial in Patients With Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
13 Feb

Pliant Therapeutics Inc - Assembles Outside Expert Panel for Beacon-Ipf Trial Review

THOMSON REUTERS
·
13 Feb

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

TipRanks
·
11 Feb

Sector Update: Health Care Stocks Retreat Monday Afternoon

MT Newswires Live
·
11 Feb

Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

GuruFocus.com
·
11 Feb

Pliant Therapeutics Shares Tumble Amid Analyst Downgrades Following Study Suspension

MT Newswires Live
·
11 Feb

Pliant Therapeutics Cut to Hold From Buy by Canaccord Genuity

Dow Jones
·
10 Feb